Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221656 · ClinicalTrials.gov registry record
Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
A clinical trial, sponsored by Mayo Clinic.
- Not yet
- Registry status
- 20
- Enrollment target
NCT07221656: Clinical Trial study, sponsored by Mayo Clinic.
NCT07221656 is a clinical trial that has not yet begun recruiting, run by Mayo Clinic. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07221656 has not yet begun recruiting, sponsored by Mayo Clinic.
- NOT YET RECRUITING
- Registry status
- 20 participants
- Enrollment target
Study Summary
This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic leukemia or lymphoma.
Primary Outcome
Descriptive statistics including medians and interquartile ranges will be utilized to summarize continuous variables.
Interventions
- OTHER Non-Interventional Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2027-02-01 |
| Est. Completion | 2028-12-31 |
What is known before NCT07221656 opens enrollment
NCT07221656 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT07221656 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07221656 about?
NCT07221656 is a clinical study titled "Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration". This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic ...
What is the current status of trial NCT07221656?
This trial is currently not yet recruiting. The enrollment target is 20 participants. The study started on 2027-02-01. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT07221656?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT07221656?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI